STEP TEENS WM: A research study on how well semaglutide helpsteenagers with excess body weight
Research type
Research Study
Full title
Weight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c. 2.4 mg Once-weekly
IRAS ID
1010799
Contact name
Clinical Transparency ((Dept 2834)
Contact email
Sponsor organisation
Novo Nordisk A/S
Eudract number
2023-508055-40
Research summary
The number of children and teenagers with excess body weight has increased a lot during the last few decades worldwide, including the UK. This excess body weight during childhood increases the risks of developing related diseases during adulthood.
Semaglutide is a medicine to treat excess body weight, and is approved for use in adults and adolescents. However, there is a knowledge gap on long-term maintenance of weight loss, as well as whether treatment can slowly be stopped, without too much of an increase in body weight. Therefore, this study will investigate long-term weight maintenance in adolescents with excess body weight.
This study will last for approximately 3-6 years (depending on the age of the teenagers when joining the study). In this study, the teenagers will be given the medicine semaglutide to check how well this medicine helps them lose weight and maintain weight loss. This study is being conducted after the study medicine ‘semaglutide’ was approved for use in adolescents. The study will be carried out at many clinics in several countries. It is an open label study which means both the researchers and the teenagers will know which medicine is being given.
About 500 teenage boys and girls, aged 12 to 15 years old will take part in this study.
REC name
London - Chelsea Research Ethics Committee
REC reference
24/LO/0698
Date of REC Opinion
13 Jan 2025
REC opinion
Further Information Favourable Opinion